Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the U.S. Food and…
On Feb. 4, 2021, Merck affirmed its position regarding use of ivermectin during the COVID-19 pandemic, and do…
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
On Feb. 3, 2021, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 7.5…
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
On Jan 28, 2021, Mammoth Biosciences announced a co-marketing agreement with Agilent Technologies to support the anticipated launch…
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
On Jan. 27, 2021, a U.S. Centers for Disease Control and Prevention (CDC) study found that the 2019-2020…
On Jan. 27, 2021, Vaxart announced that health care economic findings published in the American Journal of Preventative…
On Jan. 27, 2021, Moderna confirmed that the Company is in discussion with the U.S. government to purchase…
On Jan. 27, 2021, Pfizer and BioNTech announced results from in vitro neutralization studies of sera from individuals…
On Jan. 27, 2021, Evotec announced that the U.S. Department of Defense (DOD) awarded its Seattle, Washington-based subsidiary,…
On Jan. 26, 2021, Moderna reported that 30.4 million doses have been supplied to the U.S. Government to…
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
On Jan. 25, 2021, Oregon Health & Science University (OHSU) announced a new study demonstrated that antibodies generated…
On Jan. 22, 2021, Humanigen announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the…
On Jan. 22, 2021, Novavax announced that it had finalized an agreement with the Government of Canada to…
On Jan. 21, 2021, Zoetis announced it had as expanded its line of recombinant vector vaccines with the…
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…
On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five…
On Jan. 14, 2021, Mammoth Biosciences announced that it had secured a subcontract with MRIGlobal, the prime contractor…
On Jan. 13, 2021, National Institutes of Health scientists and their colleagues announced they had identified a S….
On Jan. 13, 2021, the Oregon Department of Agriculture (ODA) continueed to test, survey, and trap at an…
On Jan. 12, 2021, Moderna announced that Swissmedic, the Swiss Agency for Therapeutic Products, had authorized the COVID-19…
On Jan. 11, 2021, Roche announced that the European Commission (EC) had approved Xofluza (baloxavir marboxil) for the…
On Jan. 11, 2021, Baxter announced an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax COVID-19 recombinant…